ECSP055547A - Derivados de piperidina novedosos - Google Patents

Derivados de piperidina novedosos

Info

Publication number
ECSP055547A
ECSP055547A EC2005005547A ECSP055547A ECSP055547A EC SP055547 A ECSP055547 A EC SP055547A EC 2005005547 A EC2005005547 A EC 2005005547A EC SP055547 A ECSP055547 A EC SP055547A EC SP055547 A ECSP055547 A EC SP055547A
Authority
EC
Ecuador
Prior art keywords
piperidine derivatives
new piperidine
new
ccl3
mip
Prior art date
Application number
EC2005005547A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Matthew Frank Brown
Matthew Merrill Hayward
Christopher Stanley Poss
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP055547A publication Critical patent/ECSP055547A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula. en el que a, b, c, R1, R2, R3, R4, R5, R6, R7, Q, W, Y y Z son como se define anteriormente, útiles como inhibidores potentes y selectivos de la unión de MIP-1a (CCL3) a su receptor CCR1 que se encuentra en las células inflamatorias e inmunomoduladoras (preferiblemente leucocitos y linfocitos).
EC2005005547A 2002-07-18 2005-01-18 Derivados de piperidina novedosos ECSP055547A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39710802P 2002-07-18 2002-07-18

Publications (1)

Publication Number Publication Date
ECSP055547A true ECSP055547A (es) 2005-03-10

Family

ID=30770997

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005547A ECSP055547A (es) 2002-07-18 2005-01-18 Derivados de piperidina novedosos

Country Status (24)

Country Link
US (1) US20040063759A1 (es)
EP (1) EP1534677A1 (es)
JP (1) JP2005537279A (es)
KR (1) KR20050021497A (es)
CN (1) CN1668592A (es)
AP (1) AP2005003200A0 (es)
AR (1) AR040583A1 (es)
AU (1) AU2003242941A1 (es)
BR (1) BR0312946A (es)
CA (1) CA2492651A1 (es)
EC (1) ECSP055547A (es)
HN (1) HN2003000222A (es)
IL (1) IL166010A0 (es)
IS (1) IS7614A (es)
MA (1) MA27326A1 (es)
MX (1) MXPA05000380A (es)
OA (1) OA12885A (es)
PA (1) PA8575901A1 (es)
PE (1) PE20040666A1 (es)
TN (1) TNSN05014A1 (es)
TW (1) TW200402416A (es)
UY (1) UY27897A1 (es)
WO (1) WO2004009550A1 (es)
ZA (1) ZA200500067B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions
CN1867336B (zh) 2002-06-12 2010-05-12 凯莫森特里克斯股份有限公司 1-芳基-4-取代的哌嗪衍生物及其制药用途
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
EA200500033A1 (ru) * 2002-07-18 2005-06-30 Пфайзер Продактс Инк. Бициклические производные пиперидина в качестве антагонистов хемокинового рецептора ccr1
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
EP1720545B1 (en) 2004-03-03 2014-10-29 ChemoCentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
GT200500375A (es) * 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
JP4938777B2 (ja) 2005-07-26 2012-05-23 グラクソ グループ リミテッド ベンジルピペラジン誘導体およびその医薬使用
US7576218B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. 4-phenylpiperdine-pyrazole CCR1 antagonists
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
EP2202223B1 (en) * 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
US20100168080A1 (en) * 2008-12-17 2010-07-01 Khamrai Uttam Novel compounds useful as cc chemokine receptor ligands
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
EP1179341B1 (en) * 1999-05-18 2005-11-09 Teijin Limited Remedies or preventives for diseases in association with chemokines
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
SI1409477T1 (sl) * 2001-07-24 2009-02-28 Richter Gedeon Nyrt Derivati piperidina kot antagonisti nmda-receptorjev

Also Published As

Publication number Publication date
AU2003242941A1 (en) 2004-02-09
TW200402416A (en) 2004-02-16
HN2003000222A (es) 2004-11-23
MA27326A1 (fr) 2005-05-02
WO2004009550A1 (en) 2004-01-29
CA2492651A1 (en) 2004-01-29
BR0312946A (pt) 2005-07-12
IL166010A0 (en) 2006-01-15
OA12885A (en) 2006-09-15
UY27897A1 (es) 2004-02-27
MXPA05000380A (es) 2005-03-31
IS7614A (is) 2004-12-23
EP1534677A1 (en) 2005-06-01
US20040063759A1 (en) 2004-04-01
ZA200500067B (en) 2005-11-02
PA8575901A1 (es) 2004-07-20
CN1668592A (zh) 2005-09-14
JP2005537279A (ja) 2005-12-08
KR20050021497A (ko) 2005-03-07
AR040583A1 (es) 2005-04-13
TNSN05014A1 (fr) 2007-05-14
PE20040666A1 (es) 2004-09-25
AP2005003200A0 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
ECSP055547A (es) Derivados de piperidina novedosos
ECSP055548A (es) Derivados de piperidina biciclicos como antagonistas del receptor quimioquinas ccr1
ATE422198T1 (de) Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten
NO20051260L (no) Arylsubstituerte diazabicykloalkaner som nikotinacetylcholinagonister
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
HUP0500610A2 (hu) Indazol-, benzotiazol- és benzoizotiazol-származékok, ezeket tartalmazó gyógyszerkészítmények és ezek alkalmazása
EA200701114A1 (ru) Азоловые производные с антимускариновой активностью
PE20021089A1 (es) Compuestos de triazol como inhibidores de las citoquinas
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
CR9113A (es) Compuestos acetamida como fungicidas
NO20063380L (no) Triazolderivater som vasopressinantagonister
NO20083582L (no) Pyridin-2-karboksamide derivater
BRPI0409367A (pt) derivados de piperidina inibidores de renina
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
ATE338461T1 (de) Pyrazolpyrimidinfungizide
NO20061978L (no) Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon
PE20040636A1 (es) Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina
NO20071108L (no) Nye 4-benzylidenpiperidinderivater
ATE442847T1 (de) Benzimidazol-derivate als mek-hemmer
ECSP055912A (es) Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
CO5050296A1 (es) Derivados de 1-arenosulfonil-2-arilo-pirrolidina y de piperidina
GT200200095A (es) Nuevos derivados de acido sulfonico
ATE429421T1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten